Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22012
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 61–72 of 22,012 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437
View directory record Official record
Conditions
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 1 Interventional

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

NCT07060014
View directory record Official record
Conditions
Advanced Small Intestine Cancer, Appendiceal Cancers
Interventions
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Feasibility and Acceptability of Remote Saliva Collection

NCT07884474
View directory record Official record
Conditions
Survivors of Childhood Cancer, Acute Lymphoblastic Leukemia, Childhood
Interventions
Salivary Cortisol Collection, Blood Biomarker Collection, Hair Cortisol Collection, Nail Cortisol Collection, WatchPAT Sleep Assessment, Morning and Evening Diaries, MEMS Cap Adherence Monitoring, OnTimePoint Application, Survey and Questionnaire Assessment
Diagnostic Test · Behavioral · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rural Veteran and Care Partner Walking Program

NCT07914218
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Telerehabilitation Physical Activity Behavioral Intervention
Behavioral
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672
View directory record Official record
Conditions
Amyloidosis
Interventions
Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting No phase listed Observational

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
40
States / cities
Beverly Hills, California • Hemet, California • La Palma, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 2 Interventional

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

NCT06176989
View directory record Official record
Conditions
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma, Metastatic Large-cell Neuroendocrine Carcinoma, Locally Advanced Large-cell Neuroendocrine Carcinoma, Metastatic Olfactory Neuroblastoma, Locally Advanced Olfactory Neuroblastoma, Metastatic Sinonasal Undifferentiated Carcinoma, Locally Advanced Sinonasal Undifferentiated Carcinoma
Interventions
Enasidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 3 Interventional

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 4 Interventional

Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans

NCT07914673
View directory record Official record
Conditions
Healthy Adult Participants, Age 65 and Older, Age 18 to 40, Immunology
Interventions
Trivalent inactivated influenza vaccine, RabAvert
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting Phase 1Phase 2 Interventional

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

NCT06066437
View directory record Official record
Conditions
Prostate Cancer
Interventions
Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST
Recruiting No phase listed Observational

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:08 AM EST